The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000960358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/07/2026
Date registered
Help: Date registered
4/08/2026
Date last updated
Help: Date last updated
31/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1 Safety and Pharmacology Study of Oral GBP-088 in Healthy Adults
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral GBP-088 in Healthy Participants
Additional trial identifiers [1] 317638 0
GBP-088-101
Additional trial identifiers [2] 318031 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Kidney stone disease 342413 0
Condition category
Condition code
Renal and Urogenital 338550 338550 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Approximately 64 healthy men or women will be enrolled in this study. There will be two parts to the study.

In the first part of the study approximately 40 healthy men and women will be enrolled in up to 5 single ascending dose cohorts comprising 8 subjects each. Participants within each cohort will be randomised to receive a single dose of either oral GBP-088 (6 subjects) or oral placebo (2 subjects). All cohorts will be started with sentinel dosing. All doses will be administered under direct observation in the Phase 1 unit. The doses for each cohort are shown below.
Cohort SC-1: 100mg
Cohort SC-2: 300mg
Cohort SC-3: 600mg
Cohort SC-4: 1200mg
Cohort SC-5: 2000mg

A maximum of 24 additional participants in optional cohorts or cohort expansions may be considered for the first part of the study if supported by available PK and safety data and approved by the Safety Review Committee. Optional cohorts or cohort expansions will be assessed after the completion of SC-5.

In the second part of the study approximately 24 healthy men and women will be enrolled into up to 3 multiple ascending dose cohorts comprising 8 subjects each. Participants within each cohort will be randomised to receive multiple doses of either oral GBP-088 (6 subjects) or oral placebo (2 subjects). Each dose regimen will be administered twice a day for 6 days with a single dose administered on the morning of Day 7 for a total of 13 total doses. All doses will be administered under direct observation in the Phase 1 unit. The second part of the study will not occur until at least after completion of SC-4 in the first part of the study. The dose selection and dosing regimen for the second part of the study will be confirmed based upon the data from the first part of the study.
Cohort MC-1: 400mg twice a day for 6 days and a single dose on Day 7 (13 doses)
Cohort MC-2: 600mg twice a day for 6 days and a single dose on Day 7 (13 doses)
Cohort MC-3: 1000mg twice a day for 6 days and a single dose on Day 7 (13 doses)

A maximum of 16 additional participants in optional cohorts or cohort expansions may be considered for the second part of the study if supported by available PK and safety data and approved by the Safety Review Committee. Optional cohorts or cohort expansions will be assessed after the completion of MC-3.
Intervention code [1] 334468 0
Treatment: Drugs
Description of the comparator or control
Placebo control group. Placebo is oral granules for dissolution in water which will contain the excipients but without the active ingredient.
Control group
Placebo

Outcomes
Primary outcome [1] 345833 0
Assess the composite safety and tolerability of single doses of GBP-088 in healthy adult participants.
Timepoint [1] 345833 0
Treatment-emergent adverse events will be collected from the time of signing the informed consent form through the final visit which is Day 8 post dose for Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 . Physical examinations in Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 will be conducted at screening, Day -1 and Day 8 post dose. Symptom-directed physical examinations will be conducted if clinically indicated. Clinical laboratory assessments of blood and urine in Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 will be collected at screening, Day -1, Day 1, Day 2 and Day 8 post dose. ECGs in Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 will be collected at screening, Day -1, Day 1 predose and at 2, 4 and 8 hours after dosing, Day 2, Day 3 and Day 8 post dose. Vital signs in Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 will be collected at screening, on Day -1, on Day 1 predose and at 1, 2, 4, 8 and 12 hours after dosing, on Day 2 at 24 hours post dose, on Day 3 and on Day 8 post dose.
Primary outcome [2] 345834 0
Assess the composite safety and tolerability of multiple doses of GBP-088 in healthy adult participants.
Timepoint [2] 345834 0
Treatment-emergent adverse events will be collected from the time of signing the informed consent form through the final visit which is Day 14 post first dose. Physical examinations will be conducted at screening, and Day 14 post dose. Symptom-directed physical examinations will be conducted if clinically indicated at other times. Clinical laboratory assessments of blood and urine will be collected at screening, Day -1, Day 2, Day 5, Day 8 and Day 14 post dose. ECGs will be collected at screening, Day -1, Day 1 predose and at 2 and 4 after dosing, Day 3, Day 5, Day 7 predose and at 2 and 4 after dosing, Day 9 and Day 14 post dose. Vital signs will be collected at screening, on Day -1, on Days 1 through 7 predose and at 1, 2, 4, 8 and 12 hours after dosing, on Day 8, on Day 9 and on Day 14.
Secondary outcome [1] 463455 0
Plasma concentrations of GBP-088 after a single oral dose of GBP-088
Timepoint [1] 463455 0
In Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 blood will be collected for PK analyses on Day 1 pre-dose and then at 15, 30, 45, 60 and 90 minutes, and 2, 4, 6, 8, and 12 hours post dose. A 24-hour and a 36-hour post dosing sample will be collected on Day 2, a 48-hour post dosing sample will be collected on Day 3 .
Secondary outcome [2] 463459 0
Urine concentrations of GBP-088 after single oral doses of GBP-088
Timepoint [2] 463459 0
In Cohorts SC-1, SC-2, SC-3, SC-4 and SC-5 all urine voids will be collected for PK analyses on Day 1 pre-dose and then within the following windows; 0-3 hours, 3-6 hours, 6-9 hours, 9-12 hours, 12-18 hours, 18-24 hours, 24-30 hours, 30-36 hours, 36-42 hours, 42-48 hours post dose.
Secondary outcome [3] 463461 0
Plasma concentrations of GBP-088 after multiple oral doses of GBP-088
Timepoint [3] 463461 0
Blood will be collected for PK analyses on Day 1 pre-dose and then at 15, 30, 45, 60 and 90 minutes, and 2, 4, 6, 8, and 12 hours post dose. On Day 2, a 24-hour post Day 1 first dose blood for PK will be collected pre-dose. On Day 3 and Day 5, blood for PK will be collected prior to the first dose of study drug for that day. On Day 7, blood for PK will be collected pre-dose and at 15, 30, 45, 60 and 90 minutes, and 2, 4, 6, 8 and 12 hours post dose. 24-hour and 48-hour post Day 7 dose samples will be collected on Days 8 and 9, respectively.
Secondary outcome [4] 463462 0
Urine concentrations of GBP-088 after multiple oral doses of GBP-088
Timepoint [4] 463462 0
All urine voids will be collected for PK analyses on Day 1 within the following windows; 0-3 hours, 3-6 hours, 6-9 hours, 9-12 hours, 12-18 hours, and 18-24 hours post first dose. All urine voids will be collected for PK analyses on Day 7 pre-dose and then within the following windows; 0-3 hours, 3-6 hours, 6-9 hours, 9-12 hours, 12-18 hours, 18-24 hours, 24-30 hours, 30-36 hours, 36-42 hours, 42-48 hours post dose.

Eligibility
Key inclusion criteria
Deemed healthy as determined by medical history, physical examination, vital sign measurements, ECG, and laboratory safety tests
Not lactating or pregnant
Body weight at least 50kg (male) and 45kg (female) and body mass index within the range 18-32 kg/m2 (inclusive)
Capable of giving signed informed consent
Agrees to be available for all study visits and cooperates fully with the requirements of the study protocol, including the schedule of assessments
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Past or current history of moderate or severe psychiatric illness
Past or current history of mild, moderate, or severe substance abuse
Past or current history of alcohol use disorder
History of acute illness, infectious condition or chronic disease within 14 days before Screening
Any history of cardiovascular, cerebrovascular, or peripheral vascular disease
Use or intended use of prohibitied medications
Received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 30 days or 5 half-lives (whichever is longer) before Screening
Positive alcohol breath test or urine test for drugs of abuse
Positive serology panel
Clinically significant vital signs
Clinically significant laboratory abnormalities
Clinically significant history or presence of ECG findings

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated simple randomisation sequence
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment postcode(s) [1] 46003 0
2031 - Randwick

Funding & Sponsors
Funding source category [1] 322179 0
Commercial sector/Industry
Name [1] 322179 0
GondolaBio Australia Pty Ltd
Country [1] 322179 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
GondolaBio Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325081 0
None
Name [1] 325081 0
Address [1] 325081 0
Country [1] 325081 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320709 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 320709 0
Ethics committee country [1] 320709 0
Australia
Date submitted for ethics approval [1] 320709 0
01/07/2026
Approval date [1] 320709 0
29/07/2026
Ethics approval number [1] 320709 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151362 0
Dr Christopher Argent
Address 151362 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 151362 0
Australia
Phone 151362 0
+61 02 9382 5844
Fax 151362 0
Email 151362 0
Contact person for public queries
Name 151363 0
Puja Motwani
Address 151363 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 151363 0
Australia
Phone 151363 0
+61 2 9382 5820
Fax 151363 0
Email 151363 0
Contact person for scientific queries
Name 151364 0
Puja Motwani
Address 151364 0
Scientia Clinical Research Ltd. Levels 5 and 6, Bright Building, Corner High and Avoca Sts., Randwick, NSW 2031
Country 151364 0
Australia
Phone 151364 0
+61 2 9382 5820
Fax 151364 0
Email 151364 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Only aggregate participant data will be available from this study



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.